Researchers have found that sarcopenia, a condition characterized by decreased skeletal muscle mass, is strongly associated with poor treatment outcomes in lung cancer patients in response to programed death-1 (PD-1)-inhibitor therapy. However, as well as being useful for identifying patients likely to benefit from this type of therapy, early identification and treatment of sarcopenia may improve the long-term survival rates of a larger group of patients.
from Latest Science News -- ScienceDaily https://ift.tt/2TyXc0u
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment